Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|May 15, 2018
Frontline Treatment Strategies in EGFR-Mutant NSCLC
Frontline Treatment Strategies in EGFR-Mutant NSCLC
Advertisement
December 2017
- A 73-year-old Caucasian man was seen in the emergency department for severe dyspnea and chest pain
- History: symptomatic COPD managed on fluticasone and vilanterol inhaler; 50-pack/year smoking history
- Imaging studies:
- Chest X-Ray showed a large mass in the lung right upper lobe
- CT of chest, abdomen, and pelvis revealed a 6.8-cm mass right-sided mass invading the chest wall, small left pleural effusion, and several small lytic lesions in the T4/5 vertebrae
- CT-guided transthoracic needle biopsy of the lung lesion showed grade 2 adenocarcinoma
- Molecular testing, NGS: EGFR exon 21 L858R mutation
- Staging: T3N0M1
- ECOG 1
- The patient was started on osimertinib 80 mg once daily
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5